Major therapy areas by U.S. pharma revenue 2025| ��ƽ��

Leading U.S. therapy areas based on pharmaceutical revenue in 2025 (in billion U.S. dollars)

Therapy area	Revenue in billion U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Source

Release date

January 2026

More information

Region

United States

Survey time period

2025

Supplementary notes

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the ��ƽ�� OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Citation formats

In 2025, the revenues from oncology drugs in the United States totaled approximately *** billion U.S. dollars. Immunosuppressants followed with a revenue of about ** billion U.S. dollars.

High demand for drugs to treat high blood pressure

In the United States, the therapeutic class with the most prescriptions was antihypertensives, which are effective in lowering blood pressure. Sales of antihypertensives generated around **** billion U.S. dollars in 2023, representing just around *** percent of the total amount of money spent on medicines in the United States during the year.

Counting the cost of diabetes

The number of prescriptions dispensed for the use of anti-diabetes drugs stood at *** million in 2022; spending on anti-diabetic medicines increased over the last years. One reason for this could be a rise in the price of diabetes medications. When drug manufacturers own the patent to certain medicines, they can sell the product at a higher price because there is a lack of competition in the market. Prices start to fall when this market exclusivity ends, and generic versions enter the market.